Clinical trials: Advanced Malignancies
Pancreatic Neoplasm
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy.
- Trial name
- NCT00711191
- Testing
- monoclonal antibody, chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic…
- Trial name
- MAESTRO (NCT01746979)
- Testing
- TH-302, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 693 people
- Sponsor
- ImmunoGenesis
Lymphoma, Non-Hodgkin
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
This is a single-arm, single-institution, phase II study of Iodine-131 Anti-B1 Antibody for patients with previously untreated, advanced-stage (stage III or IV) low-grade non-Hodgkin's B-cell lymphoma.
- Trial name
- NCT00996996
- Testing
- Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Advanced Colorectal Adenomas, Adenocarcinoma of the Colon
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
This phase II trial studies how well Polyphenon E works in treating patients with high-risk of colorectal cancer. Polyphenon E contains ingredients that may prevent or slow colorectal cancer.
- Conditions
- Advanced Colorectal Adenomas, Adenocarcinoma of the Colon, Stage I Colon Cancer, Stage II Colon Cancer
- Trial name
- NCT01606124
- Testing
- defined green tea catechin extract, questionnaire administration, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Pancreatic Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with…
- Conditions
- Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer
- Trial name
- NCT01803282
- Testing
- Andecaliximab, Gemcitabine, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 236 people
- Sponsor
- Gilead Sciences
Breast Cancer
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast cancer over-expressing…
- Trial name
- NCT00372424
- Testing
- Herceptin, Sunitinib, Taxotere
- Where
- 7 sites in Belgium, Italy
- Volunteers
- 26 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable…
- Trial name
- NCT03284424
- Testing
- Pembrolizumab
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 159 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung…
- Trial name
- NCT04216316
- Testing
- Berzosertib, Biospecimen Collection, Carboplatin
- Where
- 34 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
ALK or ROS1-positive NSCLC
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.
- Trial name
- NCT03672643
- Testing
- Crizotinib
- Where
- 14 sites in China
- Volunteers
- 41 people
- Sponsor
- Pfizer
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
This study will define an optimal chemotherapy dose regimen of Myocet in combination with paclitaxel and intravenous Herceptin and will evaluate the efficacy and safety of this dose regimen in patients with metastatic or locally…
- Trial name
- NCT02015676
- Testing
- trastuzumab, paclitaxel, Myocet
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Monitoring and Predicting Chemotherapy Response Using DOSI
RATIONALE: New imaging procedures, such as diffuse optical spectroscopy imaging, may help measure a patient's response and allow doctors to plan better treatment.
- Trial name
- ACRIN6691 (NCT01217385)
- Testing
- DOSI
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- American College of Radiology Imaging Network
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%)…
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT03073785
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Advanced Solid Tumors
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
- Trial name
- NCT02997176
- Testing
- Talazoparib
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pfizer
Non-Hodgkin's Lymphoma
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab…
- Trial name
- NCT01332968
- Testing
- Obinutuzumab, Cyclophosphamide, Doxorubicin
- Where
- 183 sites in United States, Australia and 16 more
- Volunteers
- 1,401 people
- Sponsor
- Hoffmann-La Roche
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary objectives of the study are: To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell…
- Conditions
- Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT03088540
- Testing
- Pemetrexed, Paclitaxel, Gemcitabine
- Where
- 192 sites in Australia, Belarus and 22 more
- Volunteers
- 712 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer
The purpose of this study is to determine if the intra-tumoral injection of a subject's own dendritic cells after cryotherapy of the prostate is a safe and effective treatment for advanced prostate cancer.
- Trial name
- CRITICAL (NCT00753220)
- Testing
- VDC2008, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Bostwick Laboratories
Neoplasms
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
The primary objective of this trial is to evaluate the long-term safety of BIBF 1120 in terms of incidence and intensity of Adverse Events and changes in safety laboratory parameters.
- Trial name
- NCT00715403
- Testing
- BIBF 1120
- Where
- 11 sites in France, Germany
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Ovarian Cancer, Primary Peritoneal Cancer
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Background: The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of deoxyribonucleic acid (DNA) damage repair mechanisms.
- Conditions
- Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
- Trial name
- NCT01989546
- Testing
- BMN 673
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.